Scandion Oncology AS (OSTO:SCOL) Receivables Turnover : 0.00 (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Scandion Oncology AS Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Scandion Oncology AS's Revenue for the three months ended in Dec. 2024 was kr0.00 Mil. Scandion Oncology AS's average Accounts Receivable for the three months ended in Dec. 2024 was kr0.00 Mil.

Scandion Oncology AS Receivables Turnover Historical Data

The historical data trend for Scandion Oncology AS's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scandion Oncology AS Receivables Turnover Chart

Scandion Oncology AS Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Receivables Turnover

Get a 7-Day Free Trial

Scandion Oncology AS Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Receivables Turnover	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Scandion Oncology AS's Receivables Turnover

For the Biotechnology subindustry, Scandion Oncology AS's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scandion Oncology AS's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scandion Oncology AS's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Scandion Oncology AS's Receivables Turnover falls into.

Save Embed

;

Save Embed

;

Scandion Oncology AS Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Scandion Oncology AS's Receivables Turnover for the fiscal year that ended in Dec. 2024 is calculated as

	Receivables Turnover (A: Dec. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2024 )	/ (	(Accounts Receivable (A: Dec. 2023 )	+	Accounts Receivable (A: Dec. 2024 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Scandion Oncology AS's Receivables Turnover for the quarter that ended in Dec. 2024 is calculated as

	Receivables Turnover (Q: Dec. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Dec. 2024 )	/ (	(Accounts Receivable (Q: Sep. 2024 )	+	Accounts Receivable (Q: Dec. 2024 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Scandion Oncology AS (OSTO:SCOL) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Scandion Oncology AS Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Scandion Oncology AS's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Scandion Oncology AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scandion Oncology AS (OSTO:SCOL) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

8VY:Germany

Address

Fruebjergvej 3, Symbion, Copenhagen, DNK, 2100

Website

https://www.scandiononcology.com

Scandion Oncology AS is a clinical-stage biotechnology company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options. Cancer Drug Resistance Company discovers and develops first-in-class medicines aimed at treating cancer that is resistant to current treatment options. The company's pipeline includes products like COROST for Colorectal Cancer, PANTAX for Pancreatic Cancer, 101 for other cancer indiction, 201 for Solid Tumors.

Scandion Oncology AS Headlines

No Headlines